Vifor Pharma (GNHAF) News Today $181.25 0.00 (0.00%) As of 10/21/2022 Add Compare Share Share Headlines Stock AnalysisBuy This Stock GNHAF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Viatris, Amphastar Pharmaceuticals Get FDA Approvals of Iron Sucrose ProductsAugust 11, 2025 | marketwatch.comVifor Pharma offers £23m to NHS to resolve CMA investigationDecember 11, 2024 | msn.comVifor Pharma to pay £23m to NHS after competition probe into misleading claimsDecember 10, 2024 | msn.comEU antitrust regulators accept Vifor Pharma's pledge not to disparage rivalJuly 22, 2024 | reuters.comDrugmaker Vifor to rectify smear campaign against competitor after EU warningJuly 22, 2024 | yahoo.comVifor Pharma offers to rectify anti-competitive behaviour against rivalApril 19, 2024 | yahoo.comVifor Pharma offers to fix alleged anti-competitive behaviourApril 19, 2024 | msn.comKapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritusMay 21, 2023 | finance.yahoo.comVifor Pharma AG (VIFNE)May 10, 2023 | uk.investing.comCancellation of remaining publicly held registered shares of Vifor Pharma AGDecember 14, 2022 | financialpost.comFCancellation of remaining publicly held registered shares of Vifor Pharma AGDecember 14, 2022 | financialpost.comFApproval of extension of exemptions from SIX disclosure and publicity obligationsOctober 20, 2022 | finance.yahoo.comAustralia’s CSL raises annual profit forecast on Swiss acquisitionOctober 16, 2022 | financialpost.comFApproval of delisting of Vifor Pharma AG’s registered sharesOctober 12, 2022 | financialpost.comFCSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA NephropathyAugust 22, 2022 | finance.yahoo.comVFMCRP announces U.S. Court upholds validity of Velphoro® patentAugust 22, 2022 | finance.yahoo.comVifor Fresenius : England's NICE Recommends Tavneos For Treatment Of ANCA-associated VasculitisAugust 18, 2022 | markets.businessinsider.comTavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)August 18, 2022 | finance.yahoo.comExtension of the postponement of the settlement of Vifor Pharma tender offerJuly 13, 2022 | finance.yahoo.comAkebia Therapeutics Amends License Agreement with ViforFebruary 23, 2022 | morningstar.comMAkebia amends license agreement with Vifor for potential launch of kidney drugFebruary 23, 2022 | seekingalpha.comVifor Pharma reports sustained growth in 2021February 17, 2022 | finance.yahoo.comVifor Pharma AG Registered Shares (GNHAF)January 13, 2022 | nasdaq.comChemoCentryx's (CCXI) Stock Increases on Tavneos' FDA NodDecember 27, 2021 | finance.yahoo.comVifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®December 21, 2021 | finance.yahoo.comVifor Pharma Settles Patent Litigations Regarding Injectafer - Quick FactsDecember 20, 2021 | nasdaq.comVifor Pharma and American Regent announce settlement of Injectafer® patent litigationDecember 20, 2021 | finance.yahoo.comVifor Pharma Divests Finished Drug Product Manufacturing Business To CordenPharmaDecember 16, 2021 | nasdaq.comAustralia’s CSL to Buy Drugmaker Vifor for $11.7 BillionDecember 14, 2021 | finance.yahoo.comAustralia’s CSL to buy Swiss drugmaker Vifor for $11.7 blnDecember 14, 2021 | financialpost.comFVifor Pharma comments on media speculationDecember 13, 2021 | finance.yahoo.comUPDATE 1-European shares gain ahead of big week for central banksDecember 13, 2021 | finance.yahoo.comVifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injuryDecember 10, 2021 | finance.yahoo.comVifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive CommitteeDecember 10, 2021 | finance.yahoo.comAngion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney InjuryDecember 9, 2021 | finance.yahoo.comVifor Pharma comments on market speculationsDecember 2, 2021 | finance.yahoo.comVifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosisNovember 26, 2021 | finance.yahoo.comVifor Pharma Bolsters Its Presence In Vascular Calcification Field Via Two Acquisition DealsNovember 22, 2021 | finance.yahoo.comVFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitisNovember 12, 2021 | finance.yahoo.comVifor Pharma and Angion report topline results...October 28, 2021 | benzinga.comVifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft functionOctober 27, 2021 | finance.yahoo.comVFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in JapanSeptember 27, 2021 | finance.yahoo.comVifor Pharma's Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelinesAugust 31, 2021 | benzinga.comVifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelinesAugust 31, 2021 | finance.yahoo.comWhy Cara Therapeutics Shot Higher TodayAugust 24, 2021 | finance.yahoo.comSee Why Cara Therapeutics (CARA) Stock Is Moving Higher On TuesdayAugust 24, 2021 | feeds.benzinga.comCara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patientsAugust 23, 2021 | finance.yahoo.comCara Therapeutics, inc (CARA) Q2 2021 Earnings Call TranscriptAugust 17, 2021 | finance.yahoo.comVifor Pharma AG (VIFN)August 11, 2021 | investing.com Get Vifor Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GNHAF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNHAF Media Mentions By Week GNHAF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNHAF News Sentiment▼0.001.12▲Average Medical News Sentiment GNHAF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNHAF Articles This Week▼00▲GNHAF Articles Average Week Get the Latest News and Ratings for GNHAF and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Vifor Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies TGIFF News FFNTF News ABSCF News LBTSF News AZFL News ERBB News AVTBF News AVCNF News BIOYF News CBGL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:GNHAF) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vifor Pharma AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Vifor Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
